Biotech Business - February 4, 2026
Cereno Scientific broadens development focus for CS014
Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Biotech Business - February 4, 2026
Abera Bioscience initiates new studies in pandemic influenza
The company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza.
Careers article - February 3, 2026
Elekta is reducing the number of employees by 450
At Elekta's Strategic Update for investors the company announced that, as a consequence of the company’s new operating model, it is reducing the number of employees by 450.
Biotech Business - February 2, 2026
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.
Clinical Trials - February 2, 2026
SynAct Pharma initiates Phase 2 study in respiratory insufficiency
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Agreement - January 30, 2026
Bavarian Nordic signs distribution agreement with Eurofarma
Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.
